Single-cell analysis of CML patients bone marrow at diagnosis reveals coexistence of CD26-CD35+ healthy stem cells and CD26+CD35- CML stem cells, and how the ratio between these impacts TKI response.
Developed by Ascentage Pharma, olverembatinib is the first China -approved third-generation BCR:ABL1 inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent ...
Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...
Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial ...
This innovative tokenization initiative aims to revolutionize the mining sector by providing a new financing model for mining operations by leveraging the assets. Cunningham Mining Ltd ("CML") has ...
Genelux president, CEO and chairman Thomas Zindrick said: “The milestone holds profound significance for patients with recurrent non-small cell lung cancer who face limited therapeutic options. “This ...
Vinyas Innovative Technologies Limited was incorporated on April 27 2001 as a Private Limited Company with Registrar of Companies Bangalore in the name and style of Vinyas Innovative Technologies ...
“Congratulations to our awardees, whose innovative technologies show great promise in advancing care for pediatric heart patients,” said Kolaleh Eskandanian, VP and chief innovation officer at ...
A team of researchers from the Ivcher Institute for Brain, Cognition, and Technology (BCT Institute ... implant recipients and introduced an innovative multisensory solution that leads to notable ...